Nutraceutical formulation for unblocking receptors

Abstract

A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.

What is claimed is: 
     
         1 . A nutraceutical formulation for facilitating unblocking cannabinoid receptors, comprising:
 arachidonic acid;   docosahexaenoic acid;   echinacea;   kaempferol; and   at least one probiotic,   wherein the nutraceutical formulation is in a unit dosage form of a tablet or capsule.   
     
     
         2 . The nutraceutical formulation of  claim 1 , further comprising coffee fruit. 
     
     
         3 . The nutraceutical formulation of  claim 1 , the arachidonic acid is present in a concentration ranging from about 30 percent to about 60 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         4 . The nutraceutical formulation of  claim 1 , wherein the arachidonic acid is present in a concentration of about 46 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         5 . The nutraceutical formulation of  claim 1 , wherein the docosahexaenoic is present in a concentration ranging from about 15 percent to about 30 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         6 . The nutraceutical formulation of  claim 1 , wherein the docosahexaenoic acid is present in a concentration of about 19 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         7 . The nutraceutical formulation of  claim 1 , wherein the echinacea is present in a concentration ranging from about 1 percent to about 5 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         8 . The nutraceutical formulation of  claim 1 , wherein the echinacea is present in a concentration of about 2 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         9 . The nutraceutical formulation of  claim 1 , wherein the kaempferol is present in a concentration ranging from about 20 percent to about 40 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         10 . The nutraceutical formulation of  claim 1 , wherein the kaempferol is present in a concentration of about 33 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic. 
     
     
         11 . The nutraceutical formulation of  claim 1 , wherein the at least one probiotic is present in a concentration of about 1×10 9  CFU/g. 
     
     
         12 . The nutraceutical formulation of  claim 1 , wherein the at least one probiotic includes one of  Lactobacillus acidophilus  and  Streptococcus thermopholis.    
     
     
         13 . The nutraceutical formulation of  claim 12 , wherein the at least one probiotic is a combination of  Lactobacillus acidophilus  and  Streptococcus thermopholis.    
     
     
         14 . The nutraceutical formulation of  claim 1 , further comprising at least one aromatic spice. 
     
     
         15 . The nutraceutical formulation of  claim 14 , wherein the at least one aromatic spice is one of oregano or cinnamon. 
     
     
         16 . The nutraceutical formulation of  claim 1 , further comprising at least one excipient. 
     
     
         17 . A nutraceutical formulation for facilitating unblocking cannabinoid receptors, comprising:
 arachidonic acid in a concentration ranging from about 30 percent to about 60 percent;   docosahexaenoic acid in a concentration ranging from about 15 percent to about 30 percent;   echinacea in a concentration ranging from about 1 percent to about 5 percent;   kaempferol in a concentration ranging from about 20 percent to about 40 percent; and   at least one probiotic in a concentration of about 1×10 9  CFU/g,   wherein each concentration is calculated by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.   
     
     
         18 . The nutraceutical formulation of  claim 17 , wherein the nutraceutical formulation is in a unit dosage form of a tablet or capsule. 
     
     
         19 . A nutraceutical formulation for facilitating unblocking cannabinoid receptors, comprising:
 arachidonic acid in an amount of 8,000 mg;   docosahexaenoic acid in an amount of 3,300 mg;   echinacea in an amount of 400 mg;   kaempferol in an amount of 5,700 mg; and   at least one probiotic.   
     
     
         20 . The nutraceutical formulation of  claim 19 , wherein the nutraceutical formulation is in a unit dosage form of a tablet or capsule.